Skip to content

Atorvastatin as an Antihypertensive Agent

Effect of Atorvastatin in the Management of Hypertension

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05679102
Enrollment
120
Registered
2023-01-10
Start date
2022-12-20
Completion date
2023-01-04
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atorvastatin Antihypertensive Effect

Brief summary

This study is aimed to see the antihypertensive effect of statin (Atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. It will be a randomized controlled trial that will be done in Ayub Hospital Complex Abbottabad. After ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. They will randomly be grouped into two groups with each group comprising 60 patients. One group will be administered Amlodipine 5 mg PO once a day, while the other one will be given 5mg Amlodipine plus 10 mg Atorvastatin. The patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.

Interventions

DRUGAmlodipine 5 MG Oral Tablet

one group will be given only Amlodipine 5MG once daily

DRUGAmlodipine 5 MG / Atorvastatin 10 MG Oral Tablet

one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily

Sponsors

Ayub Teaching Hospital
CollaboratorOTHER
Khyber Medical University Peshawar
CollaboratorOTHER
Himayat Ullah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- The inclusion criteria for the study were all newly diagnosed hypertensive patients aged 35 years and above with normal lipid profile

Exclusion criteria

* Patients with a history of dyslipidemias, diabetes mellites, chronic kidney disease, and ischemic heart disease

Design outcomes

Primary

MeasureTime frameDescription
Antihypertensive effect of atorvastatin14 dayspatients receiving atorvastatin based combination should have more decrease in the blood pressure.

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026